Artemisia dracunculus / Dragon
volgens Franchomme 'l'Aromathérapie exactement'
frans : estragon, engels : tarragon, duits : estragon
familie : Asteraceae
gebruikt deel : hele bloeiende plant
Actieve bestanddelen :
methylchavicol 60-75%, linalylacetaat**
methoxy-cumarine: herniarine 0.13%
emmenagogum, menstruatiebevorderend++ (pijnlijke menstruatie)
krampstillend (spieren, zenuwen)+++
Constituants:Huile essentielle : Phénols méthyl éther : estragole, chavicol méthyl éther, anéthole
Propriétés Huile essentielle :
-Stomachique, apéritive, carminative
Applications Huile essentielle :
-Dyspepsies, flatulences, colites, hoquet, spasmes digestifs
-Toux spastiques, asthme allergique
-Contractures et crampes musculaires
-Allergies (pour le terrain)
-Dysménorrhées et spasmes gynécologiques
Risques Huile essentielle :-Eviter l’application de l’H.E. pure sur les peaux sensibles -> diluer
-Déconseillé dans les 3 premiers mois de la grossesse
-Pas d'usage prolongé sans l'avis d'un aromathérapeute
J Agric Food Chem. 2002 Nov 20;50(24):6989-92.
Antifungal constituents of the essential oil fraction of Artemisia dracunculus L. Var. dracunculus.
Meepagala KM1, Sturtz G, Wedge DE.
The isolation and structure elucidation of antifungal constituents of the steam-distilled essential oil fraction of Artemisia dracunculus are described. Antifungal activities of 5-phenyl-1,3-pentadiyne and capillarin against Colletrotichum fragariae, Colletrotichum gloeosporioides, and Colletrotichum acutatum are reported for the first time. The relative abundance of 5-phenyl-1,3-pentadiyne is about 11% of the steam-distilled oil, as determined by GC-MS. Methyleugenol was also isolated and identified as an antifungal constituent of the oil.
J Ethnopharmacol. 2004 Oct;94(2-3):283-7.
Anticonvulsant activity and chemical composition of Artemisia dracunculus L. essential oil.
Sayyah M1, Nadjafnia L, Kamalinejad M.
Artemisia dracunculus L. (Asteraceae) has been used orally as an antiepileptic remedy in Iranian folkloric medicine. The anticonvulsant potential and composition of the essential oil obtained from the aerial parts of the plant were assessed in this study. The essential oil exerted dose- and time-dependent antiseizure activity in both maximal electroshock (MES) and pentylenetetrazole models of experimental seizures with ED50 values of 0.84 and 0.26 ml/kg, respectively. At some anticonvulsant doses, the essential oil produced sedation and motor impairment assessed by rotarod test. Gas chromatography (GC)/mass spectrometry (MS) analysis of the essential oil revealed the presence of trans-anethole (21.1%), alpha-trans-ocimene (20.6%), limonene (12.4%), alpha-pinene (5.1%), allo ocimene (4.8%), methyl eugenol (2.2%), beta-pinene (0.8%), alpha-terpinolene (0.5%), bornyl acetate (0.5%) and bicyclogermacrene (0.5%) as the main components. The observed anticonvulsant and sedative effects could be related to the presence of monoterpenoids in the essential oil.
Phytomedicine. 2006 Sep;13(8):550-7. Epub 2005 Nov 2.
Antihyperglycemic activity of Tarralin, an ethanolic extract of Artemisia dracunculus L.
Ribnicky DM1, Poulev A, Watford M, Cefalu WT, Raskin I.
The studies reported here were undertaken to examine the antihyperglycemic activity of an ethanolic extract of Artemisia dracunculus L., called Tarralin in diabetic and non-diabetic animals. In genetically diabetic KK-A(gamma) mice, Tarralin treatment by gavage (500 mg/kg body wt./day for 7 days) lowered elevated blood glucose levels by 24% from 479+/-25 to 352+/-16 mg/dl relative to control animals. In comparison, treatment with the known antidiabetic drugs, troglitazone (30 mg/kg body wt./day) and metformin (300 mg/kg body wt./day), decreased blood glucose concentrations by 28% and 41%, respectively. Blood insulin concentrations were reduced in the KK-A(gamma) mice by 33% with Tarralin, 48% with troglitazone and 52% with metformin. In (STZ)-induced diabetic mice, Tarralin treatment, (500 mg/kg body wt./day for 7 days), also significantly lowered blood glucose concentrations, by 20%, from 429+/-41 to 376+/-58 mg/dl relative to control. As a possible mechanism, Tarralin was shown to significantly decrease phosphoenolpyruvate carboxykinase (PEPCK) mRNA expression by 28% in STZ-induced diabetic rats. In non-diabetic animals, treatment with Tarralin did not significantly alter PEPCK expression, blood glucose or insulin concentrations. The extract was also shown to increase the binding of glucagon-like peptide (GLP-1) to its receptor in vitro. These results indicate that Tarralin has antihyperglycemic activity and a potential role in the management of diabetic states.